GVS assessment of calcifediol (Hidroferol®)
Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already included in the Medicine Reimbursement System (GVS). Calcifediol (Hidroferol®) is indicated for treating vitamin D deficiency in adults. The Zorginstituut recommends including calcifediol in List 1A of the Health Insurance Regulation in the 0A11CCBO V cluster.
Registered indication
Calcifediol is licensed for treating vitamin D deficiency in adults, in cases where the initial administration of high doses is required or where staggered administration over time is preferred, such as in the following situations:
- as an adjuvant for treating osteoporosis;
- in patients with malabsorption syndrome;
- renal osteodystrophy;
- bone disorders induced by treatment with corticosteroid medicinal products.
The recommended dose is one capsule (0.266 mg calcifediol, equivalent to 15,960 IU vitamin D) once a month.
Review of interchangeability
The Zorginstituut carried out a marginal assessment. Based on the criteria for interchangeability, the Zorginstituut has concluded that calcifediol (Hidroferol®) is interchangeable with the other medicinal products in the GVS cluster 0A11CCBO V, which includes various products containing colecalciferol.
Zorginstiuut's advice
Calcifediol (Hidroferol®) can be put in List 1A in the 0A11CCBO V cluster. The standard dose for calcifediol can be set at 8.7 micrograms.